Company news
Innocan Pharma Corporation (CSE:INNO) news
Innocan Pharma Corporation news releases on 6ix. Latest, Oct 1, 2026: VALITIC(TM) Featured by BuzzFeed for "Magical Results," Further Strengthening Consumer…
Press releases & updates
VALITIC(TM) Featured by BuzzFeed for "Magical Results," Further Strengthening Consumer Brand Momentum
October 1, 2026
Innocan Pharma Announces First Tranche Closing of Private Placement of Units
September 23, 2026
Innocan Pharma Announces Private Placement of Units
September 9, 2026
Innocan Pharma Announces Second Quarter Fiscal year 2026 Results, With Revenue of US$5.25M (CAD 7.3M)
August 31, 2026
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
May 27, 2026
Innocan Pharma LPT-CBD is featured in Pain Medicine News
May 6, 2026
Innocan Pharma Announces Closing of Additional Debenture
April 6, 2026
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
March 31, 2026
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
March 31, 2026
Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest
March 16, 2026
Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest
March 11, 2026
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
February 27, 2026
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
February 9, 2026
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
January 27, 2026
Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering
December 10, 2025
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
November 27, 2025
InnoCan Pharma : Financial Statements as of September 30, 2025
November 26, 2025
InnoCan Pharma : MD&A Report For Nine Months Period Ended September 30, 2025
November 26, 2025
Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
November 24, 2025
Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model
November 20, 2025
Innocan Pharma to Present at the 2025 ThinkEquity Conference
October 24, 2025
Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan
October 15, 2025
Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection
September 18, 2025
Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference
September 15, 2025
CSE Bulletin: Consolidation - InnoCan Pharma Corporation (INNO)
September 2, 2025
Innocan Pharma Announces Details of Proposed Share Consolidation
August 29, 2025
InnoCan Pharma : MD&A Report For Six Months Period Ended June 30, 2025
August 28, 2025
InnoCan Pharma : Financial Statements as of June 30, 2025
August 28, 2025
Innocan Pharma Announces First Half Of 2025 Financial Results
August 27, 2025
Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada
August 22, 2025
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
July 23, 2025
Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update
July 3, 2025
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
June 20, 2025
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
June 13, 2025
Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
May 28, 2025
Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
May 6, 2025
Innocan Pharma Announces Closing of Private Placement
April 15, 2025
Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
April 7, 2025
Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million
March 31, 2025
Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited
March 7, 2025
Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest
February 27, 2025
Innocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
March 23, 2023
Innocan Pharma Announces Launch of CBD Veterinary Commercialization Team
March 17, 2023
Innocan Pharma Announces First Patent Grant in the United States
March 12, 2023
Innocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
February 21, 2023
Innocan Pharma Provides Annual "State of the Business" Update
February 16, 2023